June 12, 2021 at 12:22AM KYMRIAH (tisagenlecleucel)

KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3pQUH7y